JP2007516290A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007516290A5 JP2007516290A5 JP2006547263A JP2006547263A JP2007516290A5 JP 2007516290 A5 JP2007516290 A5 JP 2007516290A5 JP 2006547263 A JP2006547263 A JP 2006547263A JP 2006547263 A JP2006547263 A JP 2006547263A JP 2007516290 A5 JP2007516290 A5 JP 2007516290A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- compound
- aryl
- composition
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 56
- 125000000217 alkyl group Chemical group 0.000 claims 43
- 125000003118 aryl group Chemical group 0.000 claims 34
- 239000000203 mixture Substances 0.000 claims 27
- 229910052739 hydrogen Inorganic materials 0.000 claims 25
- 239000001257 hydrogen Substances 0.000 claims 25
- 125000001072 heteroaryl group Chemical group 0.000 claims 20
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 claims 20
- 229910052736 halogen Inorganic materials 0.000 claims 19
- 150000002367 halogens Chemical class 0.000 claims 19
- 125000004093 cyano group Chemical group *C#N 0.000 claims 15
- 125000000753 cycloalkyl group Chemical group 0.000 claims 15
- 150000002431 hydrogen Chemical class 0.000 claims 13
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 12
- 125000003545 alkoxy group Chemical group 0.000 claims 12
- 208000030814 Eating disease Diseases 0.000 claims 9
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 9
- 235000014632 disordered eating Nutrition 0.000 claims 9
- 125000004475 heteroaralkyl group Chemical group 0.000 claims 9
- 150000003839 salts Chemical class 0.000 claims 9
- 239000012453 solvate Substances 0.000 claims 9
- 208000008589 Obesity Diseases 0.000 claims 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- 208000035475 disorder Diseases 0.000 claims 8
- 235000020824 obesity Nutrition 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 125000003710 aryl alkyl group Chemical group 0.000 claims 7
- 208000032841 Bulimia Diseases 0.000 claims 6
- 206010006550 Bulimia nervosa Diseases 0.000 claims 6
- 208000030990 Impulse-control disease Diseases 0.000 claims 6
- 239000003937 drug carrier Substances 0.000 claims 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 6
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 5
- 125000000623 heterocyclic group Chemical group 0.000 claims 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 5
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims 5
- 229920002554 vinyl polymer Polymers 0.000 claims 5
- 239000002830 appetite depressant Substances 0.000 claims 4
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 4
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 4
- 208000030159 metabolic disease Diseases 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 238000002560 therapeutic procedure Methods 0.000 claims 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 4
- 125000001041 indolyl group Chemical group 0.000 claims 3
- 201000004384 Alopecia Diseases 0.000 claims 2
- 208000000103 Anorexia Nervosa Diseases 0.000 claims 2
- 206010003805 Autism Diseases 0.000 claims 2
- 208000020706 Autistic disease Diseases 0.000 claims 2
- 206010010219 Compulsions Diseases 0.000 claims 2
- 208000001613 Gambling Diseases 0.000 claims 2
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 2
- 102000004877 Insulin Human genes 0.000 claims 2
- 108090001061 Insulin Proteins 0.000 claims 2
- 206010022489 Insulin Resistance Diseases 0.000 claims 2
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 2
- 206010034158 Pathological gambling Diseases 0.000 claims 2
- 208000027520 Somatoform disease Diseases 0.000 claims 2
- 239000000556 agonist Substances 0.000 claims 2
- 239000005557 antagonist Substances 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 208000018459 dissociative disease Diseases 0.000 claims 2
- 208000024963 hair loss Diseases 0.000 claims 2
- 230000003676 hair loss Effects 0.000 claims 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 2
- 230000003054 hormonal effect Effects 0.000 claims 2
- 229940125396 insulin Drugs 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 125000001624 naphthyl group Chemical group 0.000 claims 2
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 2
- 230000001568 sexual effect Effects 0.000 claims 2
- 125000001544 thienyl group Chemical group 0.000 claims 2
- 210000001685 thyroid gland Anatomy 0.000 claims 2
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 claims 1
- ROJNYKZWTOHRNU-UHFFFAOYSA-N 2-chloro-4,5-difluoro-n-[[2-methoxy-5-(methylcarbamoylamino)phenyl]carbamoyl]benzamide Chemical compound CNC(=O)NC1=CC=C(OC)C(NC(=O)NC(=O)C=2C(=CC(F)=C(F)C=2)Cl)=C1 ROJNYKZWTOHRNU-UHFFFAOYSA-N 0.000 claims 1
- SXKBTDJJEQQEGE-UHFFFAOYSA-N 3-(3,5-dibromo-4-hydroxy-benzoyl)-2-ethyl-benzofuran-6-sulfonic acid [4-(thiazol-2-ylsulfamoyl)-phenyl]-amide Chemical compound CCC=1OC2=CC(S(=O)(=O)NC=3C=CC(=CC=3)S(=O)(=O)NC=3SC=CN=3)=CC=C2C=1C(=O)C1=CC(Br)=C(O)C(Br)=C1 SXKBTDJJEQQEGE-UHFFFAOYSA-N 0.000 claims 1
- 229940118148 Aldose reductase inhibitor Drugs 0.000 claims 1
- RKWGIWYCVPQPMF-UHFFFAOYSA-N Chloropropamide Chemical compound CCCNC(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1 RKWGIWYCVPQPMF-UHFFFAOYSA-N 0.000 claims 1
- QTQMRBZOBKYXCG-MHZLTWQESA-N GW 1929 Chemical compound N([C@@H](CC1=CC=C(C=C1)OCCN(C)C=1N=CC=CC=1)C(O)=O)C1=CC=CC=C1C(=O)C1=CC=CC=C1 QTQMRBZOBKYXCG-MHZLTWQESA-N 0.000 claims 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 claims 1
- 229940123659 Sorbitol dehydrogenase inhibitor Drugs 0.000 claims 1
- 229940100389 Sulfonylurea Drugs 0.000 claims 1
- 229960002632 acarbose Drugs 0.000 claims 1
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 claims 1
- 125000002252 acyl group Chemical group 0.000 claims 1
- 239000003288 aldose reductase inhibitor Substances 0.000 claims 1
- 125000005466 alkylenyl group Chemical group 0.000 claims 1
- 125000000732 arylene group Chemical group 0.000 claims 1
- 229960001761 chlorpropamide Drugs 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 229960004580 glibenclamide Drugs 0.000 claims 1
- -1 glipazide Chemical compound 0.000 claims 1
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 claims 1
- MNQZXJOMYWMBOU-UHFFFAOYSA-N glyceraldehyde Chemical compound OCC(O)C=O MNQZXJOMYWMBOU-UHFFFAOYSA-N 0.000 claims 1
- 125000005549 heteroarylene group Chemical group 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 claims 1
- 229960003105 metformin Drugs 0.000 claims 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims 1
- 229960005095 pioglitazone Drugs 0.000 claims 1
- 239000003801 protein tyrosine phosphatase 1B inhibitor Substances 0.000 claims 1
- 125000000547 substituted alkyl group Chemical group 0.000 claims 1
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 claims 1
- 229960001641 troglitazone Drugs 0.000 claims 1
- GXPHKUHSUJUWKP-NTKDMRAZSA-N troglitazone Natural products C([C@@]1(OC=2C(C)=C(C(=C(C)C=2CC1)O)C)C)OC(C=C1)=CC=C1C[C@H]1SC(=O)NC1=O GXPHKUHSUJUWKP-NTKDMRAZSA-N 0.000 claims 1
- 0 *=CC(CCCC1)N1c1cc(Cl)c(C=CC(Nc(cc2)ccc2Cl)=N)cc1 Chemical compound *=CC(CCCC1)N1c1cc(Cl)c(C=CC(Nc(cc2)ccc2Cl)=N)cc1 0.000 description 2
- NCVUODJPLGUECP-AWNIVKPZSA-N N=C(/C=C/c(cc1)ccc1-c1cc(C#N)ccc1)Nc(cc1)ccc1Cl Chemical compound N=C(/C=C/c(cc1)ccc1-c1cc(C#N)ccc1)Nc(cc1)ccc1Cl NCVUODJPLGUECP-AWNIVKPZSA-N 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US53224103P | 2003-12-23 | 2003-12-23 | |
| PCT/US2004/042934 WO2005063697A2 (en) | 2003-12-23 | 2004-12-21 | Substituted n-aryl amidines as selective d1 dopamine receptor antagonists for the treatment of obesity and cns disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007516290A JP2007516290A (ja) | 2007-06-21 |
| JP2007516290A5 true JP2007516290A5 (https=) | 2008-02-07 |
Family
ID=34738772
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006547263A Pending JP2007516290A (ja) | 2003-12-23 | 2004-12-21 | 肥満およびｃｎｓ障害の処置のための選択的ｄ１ドーパミンレセプターアンタゴニストとしての置換ｎ−アリールアミジン |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US7423149B2 (https=) |
| EP (1) | EP1706375A2 (https=) |
| JP (1) | JP2007516290A (https=) |
| CN (1) | CN1918114A (https=) |
| CA (1) | CA2550679A1 (https=) |
| WO (1) | WO2005063697A2 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2666275A1 (en) * | 2006-10-13 | 2008-04-17 | Neuromed Pharmaceuticals Ltd. | Cyclopropyl-piperazine compounds as calcium channel blockers |
| CN110437106B (zh) * | 2019-06-27 | 2021-09-07 | 广东药科大学 | 芳基脒类化合物及其合成方法 |
| CN111233744B (zh) * | 2020-02-26 | 2021-09-17 | 陕西科技大学 | （e）1-氰基-1-取代-2-（9-烷基-咔唑-3-）基-乙烯及其制备方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3106150A1 (de) * | 1981-02-13 | 1982-09-16 | Schering Ag, 1000 Berlin Und 4619 Bergkamen | "verfahren zur herstellung von imidazolessigsaeurederivaten" |
| GB8304593D0 (en) * | 1983-02-18 | 1983-03-23 | Beecham Group Plc | Amidines |
| US5681956A (en) * | 1990-12-28 | 1997-10-28 | Neurogen Corporation | 4-aryl substituted piperazinylmethyl phenylimidazole derivatives; a new class of dopamine receptor subtype specific ligands |
| AU7665694A (en) * | 1993-09-21 | 1995-04-10 | Yamanouchi Pharmaceutical Co., Ltd. | N-(3-pyrrolidinyl)benzamide derivative |
| CA2309121A1 (en) * | 1997-11-07 | 1999-05-20 | Schering Corporation | Phenyl-alkyl-imidazoles as h3 receptor antagonists |
| GB0015488D0 (en) * | 2000-06-23 | 2000-08-16 | Merck Sharp & Dohme | Therapeutic agents |
| AU2003217936A1 (en) * | 2002-03-28 | 2003-10-13 | Eli Lilly And Company | Piperazine substituted aryl benzodiazepines and their use as dopamine receptor antagonists for the treatment of psychotic disorders |
-
2004
- 2004-12-21 CA CA002550679A patent/CA2550679A1/en not_active Abandoned
- 2004-12-21 US US11/018,990 patent/US7423149B2/en not_active Expired - Fee Related
- 2004-12-21 CN CNA2004800419397A patent/CN1918114A/zh active Pending
- 2004-12-21 WO PCT/US2004/042934 patent/WO2005063697A2/en not_active Ceased
- 2004-12-21 EP EP04815055A patent/EP1706375A2/en not_active Withdrawn
- 2004-12-21 JP JP2006547263A patent/JP2007516290A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005510563A5 (https=) | ||
| JP2005507918A5 (https=) | ||
| JP5845318B2 (ja) | 嚢胞性線維症の処置のためのＡＴＰ結合カセットトランスポーターのモジュレーターとしての、１−（ベンゾ［ｄ］［１，３］ジオキソール−５−イル）−Ｎ−（フェニル）シクロプロパン−カルボキサミド誘導体および関連化合物 | |
| JP2007532651A5 (https=) | ||
| JP2013532692A5 (https=) | ||
| JP2005511656A5 (https=) | ||
| JP5623289B2 (ja) | ウイルスポリメラーゼインヒビター | |
| WO2002100846A1 (en) | Compounds and methods for the treatment or prevention of flavivirus infections | |
| US11945796B2 (en) | Substituted pyridine derivatives as SARM1 inhibitors | |
| TWI691475B (zh) | Ｕｒａｔ１抑制劑 | |
| CN111032647B (zh) | 溶血磷脂酸受体1(lpar1)抑制剂化合物 | |
| CA2464130A1 (en) | Mch antagonists for the treatment of obesity | |
| BR112021007101A2 (pt) | composto, composto para uso como neuroprotetor, sal de adição de ácido farmaceuticamente aceitável, derivado, n-óxido, solvato, tautômero, estereoisômero, racemato, sal fisiologicamente aceitável, composição farmacêutica, composições farmacêuticas neuroprotetiva e antienvelhecimento, meio tangível, agente de deleção, diminuição, ligação, inibição ou degradação de pfkfb3, inibidores de pfkfb3, de pfkfb3 para uso em neuroproteção, de atividade de quinase de pfkfb3 de molécula pequena, de atividade de quinase de pfkfb3, de molécula pequena de pfkfb3 e de molécula pequena de atividade de quinase de pfkfb3, kits para tratamento de um quadro mediado por pfkfb3 e/ou pfkfb4, de um câncer, para tratamento antienvelhecimento e para neuroproteção, métodos de imunossupressão e para tratamento de um câncer, de tumor sólido, de um câncer hematológico, de um câncer ósseo, de osteosarcoma, de doença, de isquemia cerebral, de derrame isquêmico neonatal, de insulto neurológico, de derrame isquêmico, de envelhecimento acelerado de sobrevivente de câncer, de envelhecimento acelerado de indivíduo sofrendo de hiv, de uma lesão traumática no cérebro, de um indivíduo humano após lesão no sistema nervoso central aguda, para o tratamento de um transtorno associado à modulação de níveis f-2,6-p2 em um mamífero, para tratamento ou prevenção de um transtorno ou doença relacionada à idade ou outro tratamento antienvelhecimento e para prevenção ou tratamento de consequências da quimioterapia e da radioterapia, para tratamento ou profilaxia de doença ou quadro no qual a inibição de glicólise tem efeito benéfico, de doença neurodegenerativa ou quadro no qual a inibição de glicólise tem efeito benéfico e de doença neurodegenerativa ou quadro neurodegenerativo, para intensificar o efeito de tratamento de câncer por radiação, o efeito de tratamento de câncer ósseo por radiação e o efeito de tratamento de osteosarcoma por radiação, para reduzir a capacidade de as células cancerosas repararem seu dna e reduzir inflamação aterosclerótica e/ou pelo menos uma de suas consequências clínicas, para sensibilizar a célula cancerosa para a terapia citostática e/ou de radiação, e, métodos para neuroproteção, para fabricação de uma medicação, para fabricação de uma medicação de neuroproteção, para aumento de capacidade antioxidante de célula, para reduzir uma absorção glicolítica no neurônio, para prevenção de morte apoptótica do neurônio, para reduzir uma absorção glicolítica no astrócito, para inibição reativa à proliferação de astrócito, para proteção de um neurônio contra a excitotoxicidade, para proteção de um neurônio entérico contra a excitotoxicidade, para atenuação ou prevenção de dano neuronal em um indivíduo humano, para prevenção ou tratamento de doença relacionada ao envelhecimento, para melhoria de um parâmetro, para rejuvenescimento, para radioproteção, para a mudança de biomarcador ou biomarcadores de mortalidade, para a mudança de biomarcador ou biomarcadores de longevidade ou | |
| RU2316539C2 (ru) | ПРОИЗВОДНЫЕ ПРОПИОНОВЫХ КИСЛОТ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ АКТИВАТОРОВ hPPARs. | |
| TW202128644A (zh) | 作為lpa受體拮抗劑之三唑胺基甲酸酯吡啶基磺醯胺及其用途 | |
| JP2004520377A (ja) | ヒトペルオキシソーム増殖因子活性化受容体の活性化剤としてのチアゾール及びオキサゾール誘導体 | |
| CA2933147A1 (en) | Sulfonamide derivative or pharmaceutically acceptable acid addition salt thereof | |
| JP2008513515A5 (https=) | ||
| RU2003114748A (ru) | Новые соединения, не являющиеся имидазолами | |
| KR20170042687A (ko) | 카르복실산 화합물, 이의 제조방법, 및 이의 용도 | |
| TW201437206A (zh) | ＴｒＫ阻礙化合物 | |
| JP2005509024A5 (https=) | ||
| ES2339599T3 (es) | Antagonistas del receptor de glucagon, preparacion y usos terapeuticos. | |
| JP2008530102A (ja) | グルカゴン受容体アンタゴニストとしての置換チオフェン誘導体、その調製及び治療への使用 | |
| JP2007502817A5 (https=) |